US LNG exports surge but will buyers in China turn up?
BRIDGEWATER, NJ – Tharimmune, Inc. (NASDAQ:THAR), a micro-cap biotechnology company currently valued at $2.8 million, has expanded its product pipeline with a new therapeutic candidate, HS1940, designed to target cancer through a dual-action mechanism. According to InvestingPro data, the company maintains a strong liquidity position with cash reserves exceeding debt obligations, though its stock has declined over 74% in the past year. The clinical-stage biotechnology firm today announced the development of HS1940, a multispecific biologic that binds to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF) receptors, which play crucial roles in tumor growth and immune system evasion.
HS1940 is a biparatopic biologic, capable of engaging two different sites on PD-1 and blocking VEGF simultaneously. This dual engagement is expected to offer enhanced treatment options and potentially improve outcomes for patients with various types of cancer. Tharimmune’s CEO, Randy Milby, expressed optimism about the EpiClick platform’s role in generating more potent disease-modulating therapies, emphasizing the potential benefits of targeting multiple epitopes on PD-1 and inhibiting VEGF in a single therapeutic.
The product leverages Tharimmune’s proprietary EpiClick Technology, which allows for the rapid creation of modular antibodies with high specificity and affinity toward multiple targets. While the company’s technological capabilities show promise, InvestingPro analysis reveals challenging fundamentals, with a weak overall Financial Health Score of 1.3 out of 10 and negative earnings per share of -$11.95 for the last twelve months. EpiClick’s "mix and match" approach can combine distinct antibody binding domains to create customized treatments, including those that target previously undruggable epitopes. HS1940, for example, uses a design inspired by bovine antibodies to access PD-1 epitopes not reachable by other inhibitors.
Positive target engagement data indicates that HS1940’s biparatopic format may offer broader therapeutic versatility than monospecific antibodies, which are limited to single epitope targeting. This could result in complex, synergistic anti-tumor effects. Tharimmune plans to continue preclinical testing of HS1940 and will present data at future scientific conferences, with IND-enabling studies expected to commence throughout 2025.
In addition to HS1940, Tharimmune is developing multispecific antibodies targeting HER2 and HER3, other validated cancer growth drivers. Leveraging the EpiClick platform, the company aims to create therapies that can disrupt cancer signaling in new ways and potentially overcome resistance to existing HER2-targeted treatments.
Tharimmune’s announcement is based on a press release statement and represents a forward-looking view of the company’s research and development efforts. The actual outcomes may differ, and the company’s future success in advancing HS1940 and other candidates into and through clinical trials will depend on a variety of factors, including regulatory approval processes and the results of ongoing preclinical studies. With a current ratio of 2.35, the company maintains adequate resources for near-term operations, though InvestingPro subscribers can access 11 additional key insights about Tharimmune’s financial position and market performance to make more informed investment decisions.
In other recent news, Tharimmune, Inc. announced the initiation of a Phase 2 study for its itch treatment, TH104, targeting primary biliary cholangitis (PBC) patients. This study follows promising Phase 1 results and aims to evaluate the safety and efficacy of TH104 in a nine-week trial. Additionally, the company secured approximately $2.02 million in private funding, led by Gravitas Capital and SDS Capital Group, to support clinical development and general working capital. Tharimmune also appointed Don Kim as the new Chief Financial Officer following the resignation of Thomas Hess (NYSE:HES), effective March 27, 2025. Kim brings extensive financial expertise from his previous roles at UroGen Pharma Ltd. and Strides Pharma Inc. Furthermore, Rodman & Renshaw initiated coverage on Tharimmune with a Buy rating and a 12-month price target of $17.00 per share, based on the potential future cash flows from the TH104 program. The analyst noted that the success of TH104’s development is crucial for achieving this valuation. Lastly, Tharimmune has entered licensing agreements with Intract Pharma and OmniAb to expand its product pipeline and enhance early-stage immunology research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.